Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

RegulatoryapprovedImsidolimabPositive

AI Analysis

Summary

Vanda Pharmaceuticals has received orphan designation from the European Commission for imsidolimab in the treatment of generalized pustular psoriasis, a rare dermatological condition.

Outcome Details

Granted Orphan Designation by the European Commission

Importance:6/10

Sentiment:

0.70

orphan_designationeuropedermatologyrare_disease

Related Companies

$VNDA

Read the original article

Published by yahoo_finance on August 24, 2026 11:00 AM

Read Original